{
"id":"mk19_b_hm_q002",
"number":2,
"bookId":"hm",
"correctAnswer":"C",
"title":"Question 2",
"stimulus":[
{
"type":"p",
"hlId":"4dbb95",
"children":[
"A 47-year-old woman is hospitalized with a 3-day history of progressive fatigue and shortness of breath. She completed a course of rituximab for chronic lymphocytic leukemia 2 months ago and has returned to work as a kindergarten teacher. Three weeks ago, she had a flulike illness from which she has not fully recovered. She has no other medical problems and takes no medications."
]
},
{
"type":"p",
"hlId":"37afc9",
"children":[
"On physical examination, temperature is 37.0 °C (98.6 °F), blood pressure is 110/70 mm Hg, pulse rate is 130/min, and respiration rate is 26/min. ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"Oxygen saturation"
]
},
" is 94% breathing ambient air. The skin and mucous membranes are pale. The remainder of the examination is normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a462a3",
"children":[
"Laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3980fd",
"class":"cell text l",
"children":[
"4 g/dL (40 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2989c0",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Leukocyte count",
"children":[
"Leukocyte count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"a43c5a",
"class":"cell text l",
"children":[
"6000/μL (6 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"42dff3",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Mean corpuscular volume",
"children":[
"Mean corpuscular volume"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"66b39a",
"class":"cell text l",
"children":[
"90 fL"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"7c064b",
"class":"cell text l",
"children":[
"450,000/μL (450 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"7d8e6e",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Reticulocyte count",
"children":[
"Reticulocyte count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"e3c168",
"class":"cell text l",
"children":[
"<0.1% of erythrocytes"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"a95a06",
"children":[
"Serum lactate dehydrogenase, haptoglobin, and total bilirubin levels are normal."
]
},
{
"type":"p",
"hlId":"1a0541",
"children":[
"Parvovirus polymerase chain reaction and antibody testing are positive. Bone marrow biopsy reveals a marked reduction in erythroid precursors and giant proerythroblasts with intranuclear viral inclusions."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Acyclovir"
}
},
{
"letter":"B",
"text":{
"__html":"Erythropoietin"
}
},
{
"letter":"C",
"text":{
"__html":"Intravenous immune globulin"
}
},
{
"letter":"D",
"text":{
"__html":"Prednisone"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"3b0a0f",
"children":[
"Pure red cell aplasia is characterized by normocytic or macrocytic anemia with decreased reticulocytes and absent or decreased erythrocyte precursors in the bone marrow."
]
},
{
"type":"keypoint",
"hlId":"fa4800",
"children":[
"Immunocompromised patients can have sustained parvovirus viremia, leading to acquired pure red cell aplasia and prolonged anemia requiring intravenous immune globulin to hasten viral clearance."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"170f1b",
"children":[
"The most appropriate treatment for this patient is intravenous immune globulin (IVIG) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). She has pure red cell aplasia (PRCA) characterized by normocytic anemia with decreased reticulocytes and absent or decreased erythrocyte precursors in the bone marrow and with giant proerythroblasts with intranuclear viral inclusions characteristic of parvovirus B19 infection. Several conditions have been implicated in the pathogenesis of PRCA, and chief among them are parvovirus B19 infection, thymoma, autoimmune disease (systemic lupus erythematosus), and lymphoid leukemias and lymphomas. Because of her recent chemotherapy, she is immunocompromised and vulnerable to viral infections such as parvovirus B19, which she may have been exposed to as a kindergarten teacher. Parvovirus infection in adults may be asymptomatic or associated with fever, coryza, headache, nausea, and diarrhea, followed by a rash. In adults, the classic “slapped cheek” rash may not be apparent but other cutaneous manifestations may occur. Parvovirus infection is usually transient and rarely causes clinically significant anemia in healthy patients. However, parvovirus is cytotoxic to erythrocyte precursors, and significant anemia can develop in patients with chronic hemolysis (such as sickle cell anemia) who depend on increased erythrocyte production to maintain hemoglobin levels. Immunocompromised patients can have sustained viremia leading to prolonged anemia requiring IVIG treatment to hasten viral clearance."
]
},
{
"type":"p",
"hlId":"5be58a",
"children":[
"Acyclovir has no benefit in treating parvovirus infection, and empiric use of this antiviral agent will not hasten the resolution of this patient's PRCA (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
")."
]
},
{
"type":"p",
"hlId":"9908d7",
"children":[
"Erythropoietin is appropriate to treat anemia in certain patients with myelodysplastic syndrome (MDS) or end-stage kidney disease (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). This patient has a normal platelet count and leukocyte count, which would be unlikely in MDS, and no history of chronic kidney disease, so erythropoietin is not indicated."
]
},
{
"type":"p",
"hlId":"9177a7",
"children":[
"Prednisone would be indicated with signs or symptoms of hemolytic anemia (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). However, the low reticulocyte count and normal serum lactate dehydrogenase, haptoglobin, and bilirubin levels exclude hemolytic anemia."
]
}
],
"relatedSection":"mk19_b_hm_s2_2_2",
"objective":{
"__html":"Treat pure red cell aplasia in an immunocompromised patient."
},
"references":[
[
"Means RT Jr. Pure red cell aplasia. Hematology Am Soc Hematol Educ Program. 2016;2016:51-56. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27913462",
"target":"_blank"
},
"children":[
"PMID: 27913462"
]
}
]
],
"hospitalist":false,
"hvc":false,
"peerComparison":{
"A":4,
"B":14,
"C":68,
"D":14,
"E":0
},
"hlIds":[
"4dbb95",
"37afc9",
"a462a3",
"f9867c",
"3980fd",
"2989c0",
"a43c5a",
"42dff3",
"66b39a",
"fcac73",
"7c064b",
"7d8e6e",
"e3c168",
"a95a06",
"1a0541",
"1054f1",
"3b0a0f",
"fa4800",
"170f1b",
"5be58a",
"9908d7",
"9177a7"
]
}